FGFR1 and breast cancer: These results not only indicate that FGFR1 overexpression strongly upregulates ER signaling in palbociclib-treated cells, but also suggests that palbociclib could function as an ER agonist under certain conditions in FGFR1-overexpressing breast cancer cells.